Navigation Links
Sinovac Reports Unaudited Third Quarter 2009 Financial Results
Date:11/15/2009

32,451 2,889,658 Comprehensive income attributable to stockholders $5,288,527 $780,640 $11,134,186 $7,920,085 Earnings per share - basic and diluted $0.12 $0.02 $0.26 $0.13 Weighted average number of shares of common stock outstanding - Basic 42,428,755 42,873,511 42,574,921 42,299,187 - Diluted 43,631,572 43,142,788 42,758,104 42,638,584 SINOVAC BIOTECH LTD. Consolidated Statements of Cash Flows Three Months and Nine Months Ended September 30, 2009 and 2008 (Unaudited) (Expressed in U.S. Dollars) Three Months ended Nine Months ended September 30 September 30 2009 2008 2009 2008 Cash flows from (used in) operating activities Net Income for the period $8,454,018 $1,269,963 $16,975,909 $8,450,787 Adjustments to reconcile net income to net cash used by operating activities: - deferred income taxes 551,478 (94,028) 1,399,428 (991,461) - loss (income) On disposal fixed assets 641 2,249 (6,708) 2,249 - stock-based compensation 180,152 16,635 308,195 49,907 - provision for doubtful debts (1,595,787) 408,289 717,137 1,968,207 - depreciation of property, plant and equipment, and amortization of licenses 529,957 517,751 1,394,064 1,298,314 - research and development expenditures qualified for government grant (133,176) (16,829) (261,861) (147,677) Change in other assets and
'/>"/>
SOURCE Sinovac Biotech Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
2. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
3. Sinovac to Present at 2009 UBS Global Life Sciences Conference
4. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
5. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
6. Sinovac Obtains Production License for H1N1 Vaccine
7. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
8. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
9. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
10. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
11. Sinovac Adjourns 2008 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
(Date:6/30/2015)... BOSTON , June 30, 2015  Juniper ... company focused on developing therapeutics that address unmet ... CFO George Elston will present at ... , Wednesday, July 8, 2015Time: , 4:45 PM ... NYWebcast (live & archive): , www.juniperpharma.com, under  ...
(Date:6/30/2015)... WA (PRWEB) , ... June 30, 2015 , ... ... a hydrophilic filter that does not sacrifice selectivity to achieve faster flow rates ... combines extremely fine pores with significant open space to allow easy liquid flow ...
Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... NVAX) today announced financial results for the ... $8.3 million, or $0.12 per share, for the first quarter of ... per share, for the first quarter of 2008. The Company ... 2009 and ended the quarter with $25.6 million in cash and ...
... has developed a centralised genotyping diagnostic service to ... samples taken from commercial poultry flocks. The ... of association between two isolates and thus provide ... (or not) of any such virus from a ...
... Revenues From Continuing Operations Increase 25 Percent to $62.6 ... Time -INCLINE VILLAGE, Nev., May 7 PDL BioPharma, ... financial results for the first quarter ended March 31, ... quarter of 2009 were $62.6 million, a 25 percent ...
Cached Biology Technology:Novavax Reports First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 3Novavax Reports First Quarter 2009 Financial Results 4Novavax Reports First Quarter 2009 Financial Results 5Novavax Reports First Quarter 2009 Financial Results 6Novavax Reports First Quarter 2009 Financial Results 7Novavax Reports First Quarter 2009 Financial Results 8Avian Adenovirus Genotyping Diagnostic Service 2PDL BioPharma Announces First Quarter 2009 Financial Results 2PDL BioPharma Announces First Quarter 2009 Financial Results 3PDL BioPharma Announces First Quarter 2009 Financial Results 4PDL BioPharma Announces First Quarter 2009 Financial Results 5PDL BioPharma Announces First Quarter 2009 Financial Results 6PDL BioPharma Announces First Quarter 2009 Financial Results 7PDL BioPharma Announces First Quarter 2009 Financial Results 8PDL BioPharma Announces First Quarter 2009 Financial Results 9
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/10/2015)... DALLAS , June 10, 2015 ... report "3D Sensor Market by Technology (Ultrasound, TOF, ... Application (consumer Electronics, Entertainment, Automotive) and by Geography ... published by MarketsandMarkets, the market is expected to ... CAGR of 25.51% between 2015 and 2020. ...
(Date:6/9/2015)... June 09, 2015 Research and Markets ... the "Gesture Recognition & Touchless Sensing Market ... Automotive, & Others), Product (Biometric & Sanitary Equipment) ... report to their offering. The ... expected to reach $ 23.55 Billion by 2020 ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... 4, 2014) While adults make up 95 percent of ... study from the University of Colorado School of Medicine shows ... health concern. The study, published recently in the ... several important aspects of adult vaccination. Every year, 30,000 ...
... 2014 - A recent prospective study published in ... novel simplified laboratory method of culturing embryos suggested that ... system when compared with those reported by conventional IVF ... this new method. According to the results of this ...
... A UT Arlington bioengineer has received a four-year, $1.4 ... nanoparticle system to shore up arterial walls following angioplasty ... Nguyen, a UT Arlington associate professor of bioengineering, said ... angioplasty, which opens arteries and blood vessels that are ...
Cached Biology News:Thousands of unvaccinated adults die each year from preventable diseases 2First live births with a novel simplified IVF procedure 2UT Arlington bioengineer to create new nanoparticle system to shore up arterial walls 2
... from the SMZ line is a Greenough stereomicroscope ... testing. It is available with a choice of ... space-saving compact base (N2GG). This microscope can be ... projector all at the same time giving you ...
... chemical suppression and thermally stabilized digital conductivity ... of common anions and cations over broad ... equilibrate, and fully automated with Chromeleon® SE ... maximum sample throughput at minimum cost. ...
... UNIchip AV-400 contains 400 unique human ... glass slide. The proteins, a cross ... arrayed in quadruplicate for high-quality results. ... chip layout guarantee high validity and ...
... AV-400 contains 400 unique human proteins ... slide. The proteins, all extracellular proteins ... are arrayed in quadruplicate for high-quality ... specific chip layout guarantee high validity ...
Biology Products: